AC Immune (ACIU) Stock Price, News & Analysis

Company Overview

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development. Its SupraAntigen™ platform is designed to generate active vaccines that elicit a targeted immune response against disease-associated proteins, while its Morphomer™ platform discovers small molecules that bind misfolded proteins and inhibit their toxic aggregation. Among the company’s leading assets are anti-tau vaccine candidates in mid-stage clinical trials and small-molecule inhibitors aimed at disrupting toxic oligomer formation.

AC Immune maintains collaborations and strategic partnerships with major pharmaceutical firms to accelerate development and expand global reach. Notable alliances include research agreements with Janssen Pharmaceuticals and UCB to co-develop immunotherapies for Alzheimer’s and Parkinson’s diseases, as well as partnerships with Eli Lilly and Genentech focused on diagnostic imaging agents. These collaborations strengthen AC Immune’s ability to advance its pipeline while accessing broader regulatory and commercialization expertise.

Under the leadership of CEO Dr. Andrea Pfeifer, who co-founded the company and has guided its growth since inception, AC Immune continues to invest in innovative approaches to neurodegeneration. The company’s integrated research and development model, combining both therapeutic and diagnostic strategies, aims to deliver precision solutions that address unmet medical needs in aging populations across North America, Europe and Asia.

Key Stats

• Today's Range: $2.16 to $2.23
• 50-Day Range: $1.99 to $2.45
• 52-Week Range: $1.43 to $3.98
• Volume: 104,263 shs
• Average Volume: 117,009 shs
• Market Capitalization: $220.90 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Buy

AC Immune Stock Analysis - MarketRank™

AC Immune scored higher than 44% of companies evaluated by MarketBeat, and ranked 674th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

AC Immune has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

AC Immune has a consensus price target of $10.00, representing about 354.5% upside from its current price of $2.20.

Amount of Analyst Coverage

AC Immune has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for AC Immune are expected to grow in the coming year, from ($0.62) to ($0.07) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of AC Immune is -3.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of AC Immune is -3.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

AC Immune has a P/B Ratio of 1.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.44% of the float of AC Immune has been sold short.

Short Interest Ratio / Days to Cover

AC Immune has a short interest ratio ("days to cover") of 11.5, which indicates bearish sentiment.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

AC Immune does not currently pay a dividend.

Dividend Growth

AC Immune does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.44% of the float of AC Immune has been sold short.

Short Interest Ratio / Days to Cover

AC Immune has a short interest ratio ("days to cover") of 11.5, which indicates bearish sentiment.

Change versus previous month

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 1.44

News Sentiment

AC Immune has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for AC Immune this week, compared to 1 article on an average week.

Search Interest

3 people have searched for ACIU on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, AC Immune insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.60% of the stock of AC Immune is held by insiders.

Percentage Held by Institutions

51.36% of the stock of AC Immune is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ACIU Stock Analysis - Frequently Asked Questions

How have ACIU shares performed this year?

AC Immune's stock was trading at $2.70 at the beginning of the year. Since then, ACIU stock has decreased by 18.5% and is now trading at $2.20.

How were AC Immune's earnings last quarter?

AC Immune (NASDAQ:ACIU) released its quarterly earnings data on Tuesday, August, 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by $0.05. The company earned $1.65 million during the quarter, compared to analysts' expectations of $1.98 million. AC Immune had a negative trailing twelve-month return on equity of 49.35% and a negative net margin of 174.94%.

When did AC Immune IPO?

AC Immune (ACIU) raised $55 million in an IPO on Friday, September 23rd 2016. The company issued 4,600,000 shares at $11.00-$13.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO.

Who are AC Immune's major shareholders?

AC Immune's top institutional investors include Marshall Wace LLP (0.14%), Handelsbanken Fonder AB (0.10%), Sei Investments Co. (0.02%) and Group One Trading LLC.

How do I buy shares of AC Immune?

Shares of ACIU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of AC Immune own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AC Immune investors own include Meta Platforms (META), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), Tesla (TSLA), Advanced Micro Devices (AMD) and Canopy Growth (CGC).

Company Calendar

• Last Earnings: 8/05/2025
• Today: 9/10/2025
• Next Earnings (Estimated): 11/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ACIU
• CIK: 1651625
• Web: www.acimmune.com
• Phone: (121) 345-9121
• Fax: 41-21-345-9120
• Employees: 140
• Year Founded: N/A

Price Target and Rating

• Average Price Target for AC Immune: $10.00
• High Price Target: $12.00
• Low Price Target: $8.00
• Potential Upside/Downside: +354.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.58)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$57.83 million
• Net Margins: -174.94%
• Pretax Margin: -176.80%
• Return on Equity: -49.35%
• Return on Assets: -23.16%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.33
• Quick Ratio: 1.33

Sales & Book Value

• Annual Sales: $31.02 million
• Price / Sales: 7.12
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.29 per share
• Price / Book: 1.71

Miscellaneous

• Outstanding Shares: 100,410,000
• Free Float: 95,791,000
• Market Cap: $220.90 million
• Optionable: Optionable
• Beta: 1.61